FDA Approves First Generic Version of Rosuvastatin

The U.S. Food and Drug Administration (FDA) on April 29 approved the first generic Crestor (rosuvastatin calcium) for the treatment of high triglycerides in adults, for patients with primary dysbetalipoproteinemia, and patients with homozygous familial hypercholesterolemia.

According to the FDA, “rosuvastatin calcium is in a class of drugs called statins, which … should be used in addition to a diet restricted in saturated fat and cholesterol.” The most common side effects include headache, myalgia, abdominal pain, asthenia and nausea.

Read the FDA announcement

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Lipid Metabolism, Nonstatins, Novel Agents, Primary Hyperlipidemia, Statins

Keywords: Abdominal Pain, Asthenia, Cholesterol, Cholesterol, LDL, Headache, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Myalgia, Nausea, Triglycerides, United States Food and Drug Administration

< Back to Listings